KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Share-based Compensation for 9 consecutive years, with $21.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Share-based Compensation rose 56.52% year-over-year to $21.4 million, compared with a TTM value of $73.1 million through Mar 2025, up 32.34%, and an annual FY2025 reading of $85.1 million, up 30.04% over the prior year.
  • Share-based Compensation was $21.4 million for Q1 2025 at Biocryst Pharmaceuticals, roughly flat from $21.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $21.4 million in Q1 2025 and bottomed at $12.3 million in Q3 2023.
  • Average Share-based Compensation over 3 years is $15.8 million, with a median of $14.0 million recorded in 2023.
  • The sharpest move saw Share-based Compensation fell 2.53% in 2024, then soared 56.52% in 2025.
  • Year by year, Share-based Compensation stood at $16.5 million in 2023, then grew by 29.42% to $21.3 million in 2024, then grew by 0.14% to $21.4 million in 2025.
  • Business Quant data shows Share-based Compensation for BCRX at $21.4 million in Q1 2025, $21.3 million in Q4 2024, and $17.2 million in Q3 2024.